SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Diabetes, prediabetes tied to accelerated brain aging
By
Haymarket Media
Sep 10, 2024
The association was strongest among men and people with poor cardiometabolic health.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Outdoor nighttime light exposure linked to prevalence of Alzheimer’s disease
By
Haymarket Media
Sep 06, 2024
Nighttime light exposure was more strongly linked to AD prevalence than any other disease factor among those younger than 65 years.
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
HbA1c stability tied to lower risk for Alzheimer disease and related dementias
Aug 08, 2024
The findings were seen in a large study of older veterans with diabetes.
COVID-19 continues to affect leading causes of death in US: CDC
By
Kimberly Bonvissuto
Aug 12, 2024
The COVID-19 pandemic radically altered the rankings of the leading causes of death in the United States in 2020, and although COVID ranks lower on the list of causes in 2023, its effects continue to be...
Metformin displayed a lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had the highest risk.
New report calls for more research on women’s health issues
Jul 12, 2024
The National Academies of Sciences, Engineering and Medicine analysis noted that women are disproportionately affected by chronic illnesses, including Alzheimer’s disease, depression and osteoporosis.
Pioglitazone use linked to reduced dementia risk in T2DM
Feb 16, 2023
The reduction in risk was greatest for those with a history of ischemic heart disease or stroke.